Hepion Pharmaceuticals, Inc. (HEPA) Income Statement
HEPA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsHEPA revenue and net income
HEPA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HEPA quarterly EPS vs estimates
Hepion Pharmaceuticals beat the analyst EPS estimate in 3 of the last 5 quarters.
HEPA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $30,758 | $67,131 | $77,461 | $86,073 | $34,515 | $26,737 | $18,787 | $21,938 | $21,525 |
| Gross profit | — | −$30,758 | −$67,131 | −$77,461 | −$86,073 | −$34,515 | −$26,737 | −$18,787 | −$21,938 | −$21,525 |
| Research & development | $445,512 | $11.8M | $35.6M | $33.3M | $20.4M | $12.0M | $3.2M | $7.6M | $14.3M | $15.0M |
| Sales, general & admin | $3.3M | $7.5M | $9.7M | $10.3M | $10.0M | $8.1M | $4.6M | $7.0M | $7.3M | $5.8M |
| Total operating expenses | $4.2M | $19.3M | $48.4M | $45.5M | $30.4M | $20.1M | $7.8M | $14.6M | $21.0M | $20.8M |
| Operating income | −$4.2M | −$19.3M | −$48.4M | −$45.5M | −$30.4M | −$20.1M | −$7.8M | −$14.6M | −$21.0M | −$20.8M |
| Interest income | — | — | — | — | — | — | $175,940 | $4.6M | $1.1M | $4.2M |
| Interest expense | $24,406 | $1.2M | $9,465 | $10,164 | $8,859 | $31,229 | $554,998 | $339,158 | $4.2M | $3.8M |
| Income before taxes | −$8.3M | −$16.2M | −$49.3M | −$45.1M | −$32.7M | −$20.3M | −$7.9M | −$10.0M | −$18.9M | −$17.0M |
| Income taxes | — | −$3.0M | −$409,022 | −$2.9M | $8,859 | $30,584 | −$908,682 | −$536,000 | −$3.9M | −$3.8M |
| Net income | −$8.3M | −$13.2M | −$48.9M | −$42.2M | −$32.7M | −$20.4M | −$7.0M | −$9.4M | −$15.0M | −$17.0M |
| EBITDA | −$3.7M | −$14.9M | −$49.3M | −$45.0M | −$32.6M | −$20.1M | −$7.7M | −$14.6M | −$20.6M | −$20.8M |
| EPS (diluted) | −$0.88 | −$93.75 | −$497.42 | −$461.80 | −$242.70 | −$2200.29 | −$556.19 | −$80.58 | −$42733.64 | −$217297.02 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $61,516 | $0 | $0 | $0 | $109,730 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | $30,758 | — | — | — | $12,265 | — | $18,500 |
| Gross profit | — | — | — | — | — | $30,758 | — | — | — | −$12,265 | — | −$18,500 |
| Research & development | $50,918 | $70,000 | $0 | $0 | $423,277 | $22,235 | $591,608 | $2.8M | $7.1M | $2.5M | $5.4M | $8.5M |
| Sales, general & admin | $1.2M | $728,509 | $609,683 | $527,902 | $919,488 | $1.3M | $1.8M | $1.7M | $1.4M | $2.7M | $1.8M | $2.1M |
| Total operating expenses | $1.2M | $798,509 | $609,683 | $527,902 | $1.7M | $1.3M | $1.2M | $4.5M | $8.5M | $5.2M | $7.2M | $10.7M |
| Operating income | −$1.2M | −$798,509 | −$609,683 | −$527,902 | −$1.7M | −$1.3M | −$1.2M | −$4.5M | −$8.5M | −$5.2M | −$7.2M | −$10.7M |
| Interest expense | $6,243 | $2,129 | $12,577 | $8,116 | $4,866 | $24,811 | — | $474,570 | $49,536 | $4,349 | — | $2,381 |
| Income before taxes | −$1.2M | −$810,791 | −$656,885 | −$472,506 | −$1.0M | −$6.1M | −$1.5M | −$4.9M | −$3.9M | −$5.8M | −$11.5M | −$10.5M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$3.0M | — | −$137,619 |
| Net income | −$1.2M | −$810,791 | −$656,885 | −$472,506 | −$1.0M | −$6.1M | −$1.5M | −$4.9M | −$3.9M | −$2.9M | −$11.1M | −$10.5M |
| EBITDA | −$1.2M | −$808,662 | −$365,213 | −$456,700 | −$940,019 | −$6.1M | — | −$3.9M | −$3.9M | −$5.8M | — | −$10.5M |
| EPS (diluted) | — | — | — | — | −$0.09 | −$11.11 | −$11.12 | −$0.72 | −$0.68 | −$81.23 | −$2.42 | −$137.00 |
| Gross margin | — | — | — | — | — | 50.0% | — | — | — | −11.2% | — | — |
| Operating margin | — | — | — | — | — | −2,081.7% | — | — | — | −4,722.8% | — | — |
| Net margin | — | — | — | — | — | −9,925.7% | — | — | — | −2,600.8% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HEPA's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HEPA financial results
Hepion Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $8.3 million. Diluted earnings per share came to −$0.88.
See the HEPA stock overview for the latest quote and news, or the HEPA chart for price history and technical indicators.
HEPA income statement FAQ
Does Hepion Pharmaceuticals have revenue?
Hepion Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Hepion Pharmaceuticals profitable?
No. Hepion Pharmaceuticals reported a net loss of $8.3 million in fiscal 2025.
How much does Hepion Pharmaceuticals spend on research and development?
Hepion Pharmaceuticals spent $0.4 million on research and development in fiscal 2025.
What are Hepion Pharmaceuticals's earnings per share?
Hepion Pharmaceuticals earned $-0.88 per diluted share in fiscal 2025, compared with $-93.75 a year earlier.
When does Hepion Pharmaceuticals's fiscal year end?
Hepion Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.